-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

653A.O1.6 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Bispecific T Cell Engager Therapies and Novel Targeting Agents

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
multiple myeloma, Biological, Adult, antibodies, apoptosis, Diseases, Non-Biological, Combinations, Therapies, checkpoint inhibitors, Biological Processes, Technology and Procedures, Plasma Cell Disorders, immunotherapy, cytogenetics, Lymphoid Malignancies, Study Population, Clinically relevant, pathways
Saturday, December 5, 2020: 2:00 PM-3:30 PM
Moderators:
Prashant Kapoor, MD, Mayo Clinic and Nina Shah, MD, University of California San Francisco
Disclosures:
Shah: BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar: Research Funding; GSK, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDx, Kite, Karyopharm: Consultancy.
2:00 PM

Ajai Chari, MD1, Jesus G. Berdeja, MD2, Albert Oriol3*, Niels W.C.J. Van De Donk4, Paula Rodriguez5*, Elham Askari6*, Maria-Victoria Mateos, MD, PhD7, Monique C. Minnema, MD, PhD8, Raluca Verona, PhD9*, Suzette Girgis, PhD, BPharm, MS10, Thomas Prior10*, Brandi W. Hilder, PhD10*, Jeffery Russell, MD, PhD10*, Jenna D. Goldberg, MD10* and Amrita Krishnan, MD11

1Mount Sinai Medical Center, New York, NY
2Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN
3Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
4Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands
5Clínica Universidad de Navarra, Navarra, Spain
6Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
7Hospital Clínico Universitario de Salamanca, Salamanca, Spain
8University Medical Center Utrecht, Utrecht, Netherlands
9Janssen Research & Development, Spring House, PA
10Janssen R&D, Spring House, PA
11City of Hope, Duarte, CA

2:15 PM

Deepu Madduri, MD1*, Ashley Rosko, MD2, Jason Brayer, PhD, MD3, Jeffrey Zonder4, William I. Bensinger, MD5*, Jingjin Li, PhD6*, Linzhi Xu, PhD6*, Lieve Adriaens, PharmD6*, Dhruti Chokshi, BS6*, Weijiang Zhang, PhD6*, Anita Boyapati, PhD6*, Manish Sharma, MD6*, Frank Seebach, MD6*, L. Andres Sirulnik, MD, PhD6, David M. Weinreich, MD6*, George D. Yancopoulos, MD, PhD6*, Madhav V. Dhodapkar, MD7, Suzanne Lentzsch, MD, PhD8*, Dennis Cooper, MD9 and Sundar Jagannath, MD1*

1Icahn School of Medicine at Mount Sinai, New York, NY
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
3H. Lee Moffitt Cancer Center, Tampa, FL
4Karmanos Cancer Institute, Detroit, MI
5Swedish Center for Blood Disorders and Stem Cell Transplants, Seattle, WA
6Regeneron Pharmaceuticals, Inc., Tarrytown, NY
7Emory University School of Medicine, Atlanta, GA
8Division of Hematology and Oncology, Columbia University Medical Center, New York, NY
9Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

2:30 PM

Adam D. Cohen, MD1, Simon J Harrison, MBBS MRCP (UK) PhD FRCPath (UK) FRACP2, Amrita Krishnan, MD3, Rafael Fonseca, MD4, Peter A Forsberg, MD5, Andrew Spencer6, Jesus G. Berdeja, MD7, Jacob P. Laubach, MD8, Mengsong Li9*, Voleak Choeurng9*, Anjali Vaze9*, Divya Samineni9*, Teiko Sumiyoshi9*, James Cooper9*, Bernard M Fine9* and Suzanne Trudel10

1University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA
2Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
3City of Hope, Duarte, CA
4Mayo Clinic in Arizona, Phoenix, AZ
5University of Colorado School of Medicine, Aurora, CO
6Department of Clinical Haematology, Alfred Hospital, Melbourne, VIC, Australia
7Sarah Cannon Research Institute, Nashville, TN
8Dana-Farber Cancer Institute, Boston, MA
9Genentech, Inc., South San Francisco, CA
10Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada

2:45 PM

Cesar Rodriguez, MD1, Anita D'Souza, MD, MS2, Nina Shah, MD3, Peter M. Voorhees, MD4, Ben Buelow, MD, PhD5, Ravi Vij, MBBS6 and Shaji K. Kumar, MD7

1Medical Oncology and Hematology, Wake Forest University School of Medicine, Winston-Salem, NC
2The Medical College of Wisconsin Inc., Milwaukee, WI
3Associate Professor of Medicine, University of California San Francisco, San Francisco, CA
4Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
5Teneobio, Inc., Menlo Park, CA
6Washington University School of Medicine, Ballwin, MO
7Mayo Clinic Rochester, Division of Hematology, Rochester, MN

3:00 PM

Marc S. Raab, MD1,2*, Nicola Giesen, MD2,3*, Christof Scheid, MD4, Britta Besemer5*, Kaya Miah6*, Axel Benner6*, Ivana Metzler, MD7*, Cyrus Khandanpour, PD, MD8, Andrea Seidel-Glaetzer9*, Karolin Trautmann-Grill, MD10*, Gunhild Mechtersheimer11*, Benjamin Goeppert12*, Albrecht Stenzinger13*, Hartmut Goldschmidt, MD14,15, Katja Weisel, MD16* and Manik Chatterjee17*

1Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
2Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
3Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
4Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
5Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany
6Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
7Hematology and Oncology, Frankfurt University Medical Center, Frankfurt, Germany
8Hematology, University Hospital Muenster, Muenster, Germany
9Coordinating Center for Clinical Studies (KKS), Heidelberg University, Heidelberg, Germany
10Technische Universität Dresden, University Hospital Carl Gustav Carus, Dresden, Germany
11Institute of Pathology, Heidelberg, DEU
12Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany
13Institute of Pathology, University Hospital Heidelberg, Heidelberg, DEU
14National Center for Tumor Diseases Heidelberg, Heidelberg, Germany
15Department of Hematology, Oncology, and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
16Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
17Department of Medicine II, University Hospital of Würzburg, Würzburg, Germany

3:15 PM

Fredrik Schjesvold1, Vincent Ribrag, MD2, Paula Rodriguez-Otero, MD, PhD3*, Pawel J. Robak, MD PhD4*, Markus Hansson, MD5*, Roman Hajek6*, Adrián Alegre Amor, MD, PhD7*, Joaquin Martinez-López8*, Maika Onishi9, Jorge D. Gallo10*, Aparna Raval9*, Sameer Deshpande11*, Vikram Malhi9*, Wan-Jen Hong, MD9 and Marc S. Raab, MD12*

1Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway
2Institut Gustave Roussy, Villejuif, France
3University of Navarra, Pamplona, Spain
4Medical University of Lodz, Lodz, Poland
5Skåne University Hospital, Lund, Sweden
6University Hospital of Ostrava, Ostrava, Czech Republic
7Hospital Universitario de La Princesa, Madrid, Spain
8Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
9Genentech, Inc., South San Francisco, CA
10F. Hoffmann-La Roche Ltd, Basel, Switzerland
11Syneos Health, Pune, India
12Heidelberg University Hospital, Heidelberg, Germany

*signifies non-member of ASH